DOP2023000192A - Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central y sistémicas - Google Patents
Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central y sistémicasInfo
- Publication number
- DOP2023000192A DOP2023000192A DO2023000192A DO2023000192A DOP2023000192A DO P2023000192 A DOP2023000192 A DO P2023000192A DO 2023000192 A DO2023000192 A DO 2023000192A DO 2023000192 A DO2023000192 A DO 2023000192A DO P2023000192 A DOP2023000192 A DO P2023000192A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- line
- systemic
- retrotransposons
- intercalated
- inhibitors
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000009885 systemic effect Effects 0.000 title abstract 2
- 210000003169 central nervous system Anatomy 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163161050P | 2021-03-15 | 2021-03-15 | |
| PCT/US2022/020362 WO2022197689A1 (en) | 2021-03-15 | 2022-03-15 | Line-1 inhibitors to treat cns and systemic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000192A true DOP2023000192A (es) | 2024-02-29 |
Family
ID=83321069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000192A DOP2023000192A (es) | 2021-03-15 | 2023-09-14 | Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central y sistémicas |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240173346A1 (https=) |
| EP (1) | EP4308237A4 (https=) |
| JP (1) | JP2024511973A (https=) |
| KR (1) | KR20230157430A (https=) |
| CN (1) | CN117355312A (https=) |
| AU (1) | AU2022237405A1 (https=) |
| BR (1) | BR112023018714A2 (https=) |
| CA (1) | CA3211369A1 (https=) |
| CL (1) | CL2023002746A1 (https=) |
| DO (1) | DOP2023000192A (https=) |
| IL (1) | IL305869A (https=) |
| MA (1) | MA62910A1 (https=) |
| MX (1) | MX2023010657A (https=) |
| UA (1) | UA130707C2 (https=) |
| WO (1) | WO2022197689A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12350264B2 (en) | 2019-11-22 | 2025-07-08 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorder |
| WO2021102423A1 (en) | 2019-11-22 | 2021-05-27 | Brown University | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| US20250170158A1 (en) * | 2022-02-22 | 2025-05-29 | Rome Therapeutics, Inc. | Methods of treating medical conditions using censavudine or a related compound |
| IL315480A (en) | 2022-03-15 | 2024-11-01 | Rome Therapeutics Inc | Compounds and methods for treating disease |
| WO2023178128A1 (en) * | 2022-03-15 | 2023-09-21 | Rome Therapeutics, Inc. | Methods of treating medical conditions using islatravir or a related compound |
| CA3246792A1 (en) * | 2022-03-30 | 2023-10-05 | Transposon Therapeutics, Inc. | NUCLEOSIDE LINE-1 INHIBITORS |
| WO2024129788A1 (en) * | 2022-12-13 | 2024-06-20 | Brown University | Small molecule inhibitors of the line-1 endonuclease domain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2535045T3 (es) * | 2003-04-10 | 2015-05-04 | Vanderbilt Royalty Sub L.P. | Usos y composiciones para administración de capsaicina |
| EP2965760A1 (en) * | 2014-07-09 | 2016-01-13 | Université de Montpellier | Combination of antiretroviral agents for use in the prevention or treatment of chronic inflammatory diseases |
| CN105012305A (zh) * | 2015-07-24 | 2015-11-04 | 福建广生堂药业股份有限公司 | 拉米夫定及其药用盐治疗老年性黄斑部病变的用途 |
| RU2726210C2 (ru) * | 2018-12-27 | 2020-07-09 | Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" | Комбинация противовирусных средств, набор и способ лечения на ее основе |
| EP3914604B1 (en) * | 2019-01-25 | 2026-03-04 | Brown University | Compositions comprising censavudine or elvucitabine for treating age-associated inflammation and disorders |
| TW202104210A (zh) * | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
-
2022
- 2022-03-15 KR KR1020237034983A patent/KR20230157430A/ko active Pending
- 2022-03-15 JP JP2023556734A patent/JP2024511973A/ja active Pending
- 2022-03-15 IL IL305869A patent/IL305869A/en unknown
- 2022-03-15 AU AU2022237405A patent/AU2022237405A1/en active Pending
- 2022-03-15 BR BR112023018714A patent/BR112023018714A2/pt unknown
- 2022-03-15 CN CN202280034771.5A patent/CN117355312A/zh active Pending
- 2022-03-15 MX MX2023010657A patent/MX2023010657A/es unknown
- 2022-03-15 US US18/550,498 patent/US20240173346A1/en active Pending
- 2022-03-15 WO PCT/US2022/020362 patent/WO2022197689A1/en not_active Ceased
- 2022-03-15 EP EP22772048.9A patent/EP4308237A4/en active Pending
- 2022-03-15 CA CA3211369A patent/CA3211369A1/en active Pending
- 2022-03-15 UA UAA202304574A patent/UA130707C2/uk unknown
- 2022-03-15 MA MA62910A patent/MA62910A1/fr unknown
-
2023
- 2023-09-14 CL CL2023002746A patent/CL2023002746A1/es unknown
- 2023-09-14 DO DO2023000192A patent/DOP2023000192A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022237405A1 (en) | 2023-11-02 |
| UA130707C2 (uk) | 2026-04-22 |
| WO2022197689A1 (en) | 2022-09-22 |
| KR20230157430A (ko) | 2023-11-16 |
| MA62910A1 (fr) | 2023-12-29 |
| EP4308237A1 (en) | 2024-01-24 |
| CL2023002746A1 (es) | 2024-04-05 |
| EP4308237A4 (en) | 2025-03-05 |
| US20240173346A1 (en) | 2024-05-30 |
| CN117355312A (zh) | 2024-01-05 |
| MX2023010657A (es) | 2023-09-21 |
| BR112023018714A2 (pt) | 2023-10-24 |
| IL305869A (en) | 2023-11-01 |
| CA3211369A1 (en) | 2022-09-22 |
| JP2024511973A (ja) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000192A (es) | Inhibidores de los retrotransposones largos intercalados del elemento 1 (line-1) para tratar enfermedades del sistema nervioso central y sistémicas | |
| CL2021002267A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945) | |
| CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
| CL2020003330A1 (es) | Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018) | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CL2021002966A1 (es) | Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer. | |
| EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
| UY38948A (es) | Régimen de dosificación para agentes anti-dll3 | |
| CL2024000867A1 (es) | Compuestos de imidazopiridazina inhibidores de il-17. | |
| TNSN07482A1 (fr) | Nouvelles compositions injectables et procede de preparation desdites compositions | |
| BR0317361A (pt) | Método de tratamento, prevenção ou inibição de um distúrbio do snc e/ou dor e inflamação utilizando uma associação de duloxetina, venlafaxina ou atomoxetina e um inibidor seletivo da ciclooxigenase-2 e suas formulações | |
| MX2024006769A (es) | Compuestos y usos de los mismos. | |
| MX2025013118A (es) | Tratamiento combinado para una enfermedad o un trastorno relacionado con ras | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| CL2022001102A1 (es) | Métodos para el tratamiento de trastornos depresivos. | |
| BR112022018115A2 (pt) | Inibidor de cxcr4 para o tratamento de síndrome de desconforto respiratório agudo e infecções virais | |
| MX2023003332A (es) | Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades. | |
| CO2022014343A2 (es) | Composiciones y métodos para el tratamiento de lesión o hemorragia por reperfusión después de la terapia de recanalización | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MXPA04001398A (es) | Metodo para el tratamiento y prevencion de dolor e inflamacion con glucosamina y un inhibidor selectivo de ciclooxigenasa-2 y composiciones para el mismo. | |
| MX2022011519A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal. | |
| MX2024011916A (es) | Inhibidores de retrotransposones del elemento 1 intercalado largo (line-1) tipo nucleosido | |
| MX2022003945A (es) | Metodo para tratar vih con cabotegravir y rilpivirina. | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. | |
| MX2023011720A (es) | Una composicion para su uso en el tratamiento de mhc-i-opatias. |